Save

Autologous Tumour Vaccine Trial

PHASE1RECRUITING

Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents.

Simpliy with AI

Study details:

Radvax is a newly developed vaccine where extracted autologous tumour proteins are combined with the non-inflammatory Advax delta inulin adjuvant. Cancer immunotherapy has had a renewed interest due to the recent success and regulatory approval of immune checkpoint inhibitors and CAR-T cells. However, only a proportion of cancer patients derive benefit from these agents and hence there is an ongoing need to improve outcomes of patients with advanced solid tumours.

Radvax is a novel simplified ATV approach whereby soluble tumour antigens are extracted from tumour samples obtained at surgery or from biopsy and formulated with Advax adjuvant. This vaccine has shown efficacy in murine models of glioma and pancreatic cancer, clinical trials of canine cancer patients. Radvax is now being assessed in a Phase 1 clinical trial of advanced solid cancers.

Autologous tumour vaccines (ATV) will be generated from surgically removed or biopsied fresh tumour tissue. ATV is manufactured as a tumour lysate extract which is stored frozen, and then formulated with Advax adjuvant on day of administration. Doses of ATV will be administered on days 1, 8, 15, 22 during cycle 1 and then 4 weeks thereafter until total of up to 12 cycles Primary Endpoint(s): Incidence of grade 3 or 4 adverse effects Secondary Endpoint(s): Response rates by iRECIST, progression free survival and overall survival Exploratory Endpoints: To study parameters and predictive biomarkers of cancer response.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Subjects must have histologically or cytologically confirmed advanced solid cancers or hematological cancers (lymphomas only)

Subjects must have received at least one prior therapy for this disease, with the exception that subjects for whom no standard therapy options exist or who decline standard therapies can be considered for inclusion after discussions with the investigator team.

Performance status ≤ 2 (ECOG performance status)

Subjects or their parents if a child must have the ability to understand and the willingness to sign a written informed consent document.

If no suitable cancer tissue is already available to make the vaccine, to be enrolled in the trial participants must be willing to undergo surgery and/or fresh tumour biopsy to obtain tissue to allow the preparation of the vaccine and their primary care team needs to have agreed to perform these procedures for them to obtain tumour tissue. The trial team will provide advice on appropriate tissue collection and arrange transport and processing but are not responsible for arranging such surgery or paying for its cost.

Exclusion criteria

Subjects receiving any other investigational agents within the preceding 4 weeks.

Pregnant women because of the unknown risk of adverse events in the foetus secondary to treatment of the mother with ATV.

Any potential participant where suitable cancer tissue is not available for preparation of the vaccine

Any condition that the Investigator deems may make a potential participant unsuitable for entry into the trial.

Simplify with AI

Eligibility

Age eligible for study : 0 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2023-02-10

Primary completion: 2026-02-10

Study completion finish: 2028-02-10

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05807035

Intervention or treatment

BIOLOGICAL: Radvax

Conditions

• Solid Tumor

Condition: Solid Tumor
BIOLOGICAL: Radvax
Adelaide, South Australia, Australia
Sponsor: Vaxine Pty Ltd

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

ARASMI

Research sites nearby

Select from list below to view details:

ARASMI
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Radvax This is a single arm study where all participants will get active Radvax autologous tumour vaccine weekly for 4 weeks and then monthly thereafter	BIOLOGICAL: Radvax Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of grade 3 or 4 adverse effects	Incidence of grade 3 or 4 adverse effects related to vaccine administration	Interval from time of vaccination to 7 days post vaccination

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Progression free survival	Progression free survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Overall survival	Overall survival	From date of randomization to date of death from any cause, assessed up to 60 months
Response rate by RECIST version 1.1	modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials	From date of randomization, assessed each 6 months up to 60 months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Autologous Tumour Vaccine Trial